Cerus Corporation (Nasdaq:CERS) announced today a new corporate branding campaign building upon the Company’s leadership position in helping to safeguard the world’s blood supply and the planned relocation of its corporate offices to a new facility in Concord California. The new facility will consolidate all non-field based, U.S. employees into one location, facilitating greater teamwork and communication, and allowing for future expansion as the business grows.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190603005276/en/
1220 Concord Avenue (Photo: Business Wire)
The new corporate brand reflects Cerus’ increasingly important role in helping blood centers globally to proactively protect the blood supply against the threat of known and emerging infectious diseases. The Company aims to be the global leader in pathogen reduction technologies and a trusted partner of blood centers and hospitals.
“After over two decades of sustained effort to support blood centers and national transfusion services in adopting our INTERCEPT system as their standard of care, Cerus is entering the next chapter of our planned growth and evolution. The new corporate brand and global headquarters provide Cerus with an improved foundation going forward,” said William ‘Obi’ Greenman, Cerus’ president and chief executive officer. “Since our inception, as we expanded operations, we grew into three separate buildings in Concord. The new office provides a scalable workspace to support our multi-year growth strategy, while our new brand identity embodies our goal to be a world class partner for an increasing number of blood centers around the globe.”
Executive, sales administration, finance, and clinical functions are now located in the new facility. Research and development and regulatory are expected to relocate later this month.
The new headquarters will be located at 1220 Concord Avenue and occupy nearly 85,000 square feet compared to the approximately 72,000 square feet combined in Cerus’ three previous buildings. The site in Concord was chosen to take advantage of Cerus’ existing presence in the city which has supported the Company’s growth since the early 1990s and the location benefits for recruiting talent in the San Francisco Bay Area.
For additional information about Cerus new corporate brand, visit www.cerus.com/blood-matters.
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Based in Concord, California, our employees are dedicated to deploying and suppling vital technologies and pathogen-protected blood components for blood centers, hospitals and ultimately patients who rely on safe blood. With the INTERCEPT Blood System, we are focused on protecting patients by delivering the full complement of reliable products and expertise for transfusion medicine. Cerus develops and markets the INTERCEPT Blood System, and remains the only company in the blood transfusion space to earn both CE Mark and FDA approval for pathogen reduction of both platelet and plasma components. Cerus currently markets and sells the INTERCEPT Blood System in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. For more information about Cerus, visit www.cerus.com.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.